Biogen Idec launches Fampyra in Ireland

Biogen Idec has announced the launch of its multiple sclerosis drug Fampyra in Ireland, following its successful introduction in other parts of Europe.

The therapy is intended for the symptomatic treatment of walking impairment in adults with multiple sclerosis (MS). It is a prescription drug that is licensed for use in all types of the disease, including its progressive forms.

In clinical trials such as the pivotal MS-F203 phase III study, Fampyra demonstrated efficacy in improving walking speed among a significant amount of patients. Treatment effect is usually evident within two to four weeks.

This is an important new therapy option due to the fact that walking and mobility are rated among the leading health concerns for people with MS.

Terry O'Regan, vice-president and managing director of Biogen Idec, said: "As a leading company in MS, we feel a strong sense of obligation to the MS community to bring new and innovative therapies to the people that need them."

Earlier this month, the company announced the formation of a new partnership with Sangamo BioSciences, which will focus on the development of new treatments for haemoglobinopathies.